Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
8.93
+0.07 (0.79%)
At close: Jan 2, 2026, 4:00 PM EST
8.95
+0.02 (0.22%)
After-hours: Jan 2, 2026, 4:45 PM EST
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $53.81M in the quarter ending September 30, 2025, with 363.61% growth. This brings the company's revenue in the last twelve months to $66.50M, up 112.57% year-over-year. In the year 2024, Tango Therapeutics had annual revenue of $42.07M with 15.17% growth.
Revenue (ttm)
$66.50M
Revenue Growth
+112.57%
P/S Ratio
14.73
Revenue / Employee
$429,039
Employees
155
Market Cap
1.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 42.07M | 5.54M | 15.17% |
| Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
| Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
| Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
| Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
| Dec 31, 2019 | 24.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TNGX News
- 16 days ago - Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy - Seeking Alpha
- 2 months ago - Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript - Seeking Alpha
- 2 months ago - Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement - Benzinga
- 2 months ago - Tango Therapeutics Announces $225 Million Financing - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 - GlobeNewsWire
- 4 months ago - Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference - GlobeNewsWire